Horizon Discovery and Genewell Biotechnology enter into partnership for distribution of diagnostic reference standards for the Chinese market

Partnership immediately provides Horizon with deeper access to Chinese diagnostic assay manufacturers and potential OEM agreements as part of stated global leadership strategy.

Video of the Week - Dr Elisa Passini on winning the 2017 3Rs Prize

Dr Elisa Passini (Department of Computer Science, University of Oxford) is the 2017 3Rs Prize winner. Here she discusses her prize-winning research into the development of computer models of human cardiac cells for the prediction of drug-induced cardiotoxicity. These have the potential to replace animal models in pre-clinical trials, as well as providing a more accurate model of human cardiac activity.

Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation

Astex Pharmaceuticals , a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.

Domainex appoints Dr Bodo Spori as Head of Business Development for Europe

Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.

NovaBiotics’ Lynovex receives Fast Track Designation for Cystic Fibrosis Exacerbations

NovaBiotics Ltd (NovaBiotics), a clinical-stage anti-infectives biotechnology company, announces receipt of Fast Track Designation (FTD) for its cystic fibrosis (CF) therapy, Lynovex®, from the United States Food and Drug Administration (FDA).

BIA visits an animal research facility

The BIA team recently visited the animal research facilities at King’s College London. It was the first time many in the team had visited animal research facilities to see how pre-clinical research looks in practice.

Steady as she goes in the Spring Statement

Dr Martin Turner, BIA Policy and Projects Manager, takes a look at today's Spring Statement from Chancellor Phillip Hammond and its implications for the bioscience sector.

CEO Update: Monday 12 March

Today, the Business Secretary Greg Clark has announced that the government is investing over £300 million from its Industrial Strategy Challenge Fund (ISCF) to bring together the UK’s world-class research expertise with business investment to develop technologies and industries that can help the UK prepare for the challenge of an ageing society. £210 million will be invested in the ‘data to early diagnosis and precision medicine’ challenge which will see the UK lead the world in the development of innovative new diagnostic tools, medical products and treatments.

Profiling your organisation on the new BIA website

The new and improved BIA website isn’t just sleeker and more user-friendly, it also comes with lots of new functions to help BIA member companies to raise their profile more effectively. One such functionality is the ability for members to upload their news and job vacancies directly to the website, for the BIA team to approve and publish.

Don’t get frozen out by the Scottish Lobbying Act

Last week, the BIA was all set to head North for the annual Scottish Life Sciences Awards Dinner and a lunch meeting with our members when the Beast from the East hit and all flights were grounded. So sadly, I didn’t get the opportunity to speak to our members about the Scottish Lobbying Act and how it could affect them. Instead, I’ve explained it all here so if you’re not too snowed under with work, do read on…